Sensus Healthcare, Inc. (NASDAQ:SRTS) Sees Significant Drop in Short Interest

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 1,180,000 shares, a drop of 23.9% from the January 31st total of 1,550,000 shares. Approximately 8.8% of the company’s shares are sold short. Based on an average daily volume of 335,000 shares, the days-to-cover ratio is currently 3.5 days.

Sensus Healthcare Price Performance

Shares of Sensus Healthcare stock opened at $4.46 on Tuesday. The business has a 50-day moving average of $6.49 and a 200 day moving average of $6.79. Sensus Healthcare has a 12 month low of $2.91 and a 12 month high of $9.33. The stock has a market capitalization of $73.09 million, a price-to-earnings ratio of 11.15 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. Equities research analysts anticipate that Sensus Healthcare will post 0.32 earnings per share for the current year.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new position in Sensus Healthcare during the 4th quarter valued at about $27,000. Barclays PLC purchased a new position in shares of Sensus Healthcare in the 4th quarter valued at about $35,000. Truvestments Capital LLC purchased a new position in shares of Sensus Healthcare in the 3rd quarter valued at about $32,000. BNP Paribas Financial Markets purchased a new position in shares of Sensus Healthcare in the 4th quarter valued at about $47,000. Finally, IFP Advisors Inc purchased a new position in shares of Sensus Healthcare in the 4th quarter valued at about $95,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SRTS has been the subject of a number of recent analyst reports. Lake Street Capital initiated coverage on Sensus Healthcare in a research report on Friday, January 31st. They set a “buy” rating and a $18.00 price objective for the company. Maxim Group raised their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, HC Wainwright raised their price objective on Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Monday, February 10th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.